Table 2.
RPT agents that are available or under investigation
| RPT agent | Company | Indication |
|---|---|---|
| 131I-radioiodine | Malincrodt/Jubilant Draximage | Thyroid cancer |
| 131I -MIBG | Progenics | Adrenergic+ tumors |
| 212Pb-trastuzumab | ArevaMed | HER2+ tumors |
| 212Pb -aSSR | ArevaMed/Radiomedix | Somatostatin+ tumors |
| 212Pb -aTEM1 | ArevaMed/Morphotek | TEM1+ tumors |
| 212Pb -aCD37 | ArevaMed/NordicNanovector | Leukemia |
| 131I -aCD45 | Actinium Pharmaceuticals | BM xplant prep |
| 225Ac-aCD33 | Actinium Pharmaceuticals | Leukemia |
| 90Y-microspheres | Varian/Sirtex | Hepatic malignancies |
| 90Y -microspheres | BTG | Hepatic malignancies |
| Lutathera (177Lu) | Novartis/AAA | Somatostatin+ tumors |
| 177Lu -aPSMA-R2 | Novartis/AAA | Prostate, tumor neovasc. |
| 177Lu -NeoBOMB1 | Novartis/AAA | Bombesin+ tumors |
| Xofigo (223Ra) | Bayer | Bone mets |
| HER2-TTC (227Th) | Bayer | HER2+ tumors |
| PSMA-TTC (227Th) | Bayer | Prostate, tumor neovasc. |
| MSLN-TTC (227Th) | Bayer | Mesothelin+ tumors |
| CD22 TTC (227Th) | Bayer | Lymphoma |
| FPX-01 (225Ac) | J&J/Fusion Pharma | NSCLC, pan-cancer target |